ReviewFrontiers in endocrinology2023
Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07316075 (Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and Paragangliomas), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and Paragangliomas
Who cites it
30 citing papers in PubMed, 38 citations in OpenAlex.
- A Rare Presentation of Tuberculosis: Dilated Cardiomyopathy Secondary to Myocarditis with a Dual-secretory Adrenal Pheochromocytoma.Annals of African medicine · 2026Article
- Ruptured pheochromocytoma presenting with acute myocardial injury and hemoperitoneum.JCEM case reports · 2026Article
- A rare case of pheochromocytoma-induced reverse Takotsubo cardiomyopathy presenting as a catecholaminergic crisis.Hormones (Athens, Greece) · 2026Article
- Pheochromocytoma multisystem crisis presenting with abdominal pain in an adolescent: a case report.BMC pediatrics · 2026Article
- Resolution of reverse takotsubo cardiomyopathy secondary to presumed pheochromocytoma with intralesional hemorrhage.JCEM case reports · 2026Article
- Article
- Emerging Mechanisms and Therapeutic Strategies in Dilated Cardiomyopathy.Biomedicines · 2026Review
- Predicting Hemodynamic Fluctuations During Adrenalectomy for Pheochromocytoma.Diagnostics (Basel, Switzerland) · 2026Article
- Pheochromocytoma complicated with acute myocardial infarction and cerebral infarction: a case report.Frontiers in oncology · 2026Article
- Fluctuating hypertension possibly leading to severe cardiomyopathy in SDHB-associated hereditary paraganglioma: from heart transplant candidacy to long-term lanreotide management: a case report.Frontiers in cardiovascular medicine · 2026Article
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- Cardiac Endocrine Function and Hormonal Interplay in Pediatrics: From Development to Clinical Implications.Biomedicines · 2025Review
- Pheochromocytoma: a case report of a rare culprit of heart failure in the peripartum period.European heart journal. Case reports · 2025Article
- Hearing the Hoofbeats of Pheochromocytoma in New-Onset Cardiomyopathy Leads to Success Instead of Failure.JACC. Case reports · 2025Article
- ECMO-Assisted Da Vinci Robotic Surgery for Pheochromocytoma-Induced Acute Catecholamine Cardiomyopathy: A Case Report.Clinical case reports · 2025Article
- The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management.International journal of molecular sciences · 2025Review
- Article
- Metabolically active brown adipose tissue in PPGL: an observational cohort study.Endocrine-related cancer · 2025Observational
- Pheochromocytoma-Induced Reversible Dilated Cardiomyopathy: A Case Report and Literature Review.Clinical case reports · 2025Article
- Urinary bladder paraganglioma presenting with abdominal pain and elevated cardiac enzymes: a case report of atypical manifestations and diagnostic challenges.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that frequently produce and release catecholamines. Catecholamine excess can manifest in several cardiovascular syndromes, including cardiomyopathy. PPGL-induced cardiomyopathies occur in up to 11% of cases and are most often associated with an adrenal pheochromocytoma (90%) and rarely with a paraganglioma derived from the sympathetic ganglia (10%). PPGL-associated cardiomyopathies can be chronic or acute, with takotsubo cardiomyopathy being the most often reported. These two types of PPGL-induced cardiomyopathy seem to have different pathophysiological backgrounds. Acute catecholaminergic stress inundates myocardial β-adrenoceptors and leads to left ventricle stunning and slight histological apoptosis. In chronic cardiomyopathy, prolonged catecholamine exposure leads to extended myocardial fibrosis, inflammation, and necrosis, and ultimately it causes dilated cardiomyopathy with a low ejection fraction. Sometimes, especially in cases associated with hypertension, hypertrophic cardiomyopathy can develop. The prognosis appears to be worse in chronic cases with a higher hospital mortality rate, higher cardiogenic shock rate at initial presentation, and lower left ventricular recovery rate after surgery. Therefore, establishing the correct diagnosis at an early stage of a PPGL is essential. This mini-review summarizes current data on pathophysiological pathways of cardiac damage caused by catecholamines, the clinical presentation of PPGL-induced cardiomyopathies, and discusses treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.